We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

bioMérieux

Designs, develops, manufactures and markets in vitro diagnostics systems used in clinical and industrial applications read more Featured Products: More products

Download Mobile App





bioMérieux Showcases Advanced Generation of VIDAS Immunoassay Solution

By LabMedica International staff writers
Posted on 05 Feb 2024
Print article
Image: The VIDAS KUBE next generation system in the VIDAS immunoassay portfolio is highlighted at Medlab Middle East 2024 (Photo courtesy of bioMérieux)
Image: The VIDAS KUBE next generation system in the VIDAS immunoassay portfolio is highlighted at Medlab Middle East 2024 (Photo courtesy of bioMérieux)

bioMérieux (Marcy l'Etoile, France) is participating in Medlab Middle East 2024 as a Diamond Partner where the company is sharing its game-changing innovations. Visitors to the bioMérieux booth can discover, and exchange insights on antimicrobial stewardship, sepsis management, point-of-care solutions, and emergency care, among others.

At Medlab Middle East 2024, bioMérieux is presenting its recently launched VIDAS KUBE, the advanced generation of its VIDAS immunoassay solution which has been trusted by labs around the world for more than 30 years. VIDAS has transformed the field of immunoassays offering laboratories universal access to a simple, automated, and robust technology providing fast and reliable results. Featuring a single-test concept in an all-in-one kit, VIDAS is currently used in more than 160 countries by 25,000 laboratories. It is still one of the most widely used immunoassay systems in clinical laboratories worldwide. VIDAS KUBE, the latest addition to this innovative range, combines advanced technology with the recognized values of the VIDAS solution. The new VIDAS KUBE features a stackable and modular benchtop design and easy implementation that will benefit clinical diagnostic labs. It is compatible with the existing broad routine test menu covering emergency and critical care, immunochemistry, and infectious diseases.

In addition, bioMérieux is showcasing VITEK MS PRIME, a next-level automated MALDI-TOF Mass Spectrometry system that enables accurate microbial identification to the species level. This benchtop high-throughput automated identification system has a robust database, which includes intra-species diversity, and delivers fast and confident microbial identification. The system has the features required to ensure compliance, and you can rely on our validation experts to implement this solution quickly and efficiently. bioMérieux is also highlighting the VITEK REVEAL rapid Antimicrobial Susceptibility Testing, integrated into its Sepsis Solution to help better manage bloodstream infections. Among its point-of-care diagnostic solutions, bioMérieux is highlighting the BIOFIRE SPOTFIRE System which is the latest advancement in molecular infectious disease diagnostics. All of the company’s expertise and cutting-edge FILMARRAY technology are at the heart of the system design. Within its point-of-care respiratory testing solutions, bioMérieux is spotlighting the BIOFIRE SPOTFIRE Respiratory Panels which offer rapid syndromic PCR tests for a range of common pathogens.

Related Links:
bioMérieux 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Nutating Mixer
Enduro MiniMix
New
PSA Test
Humasis PSA Card

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
MEDLAB 2024
Copyright © 2000-2025 Globetech Media. All rights reserved.